Clinical Trial Update: Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for INX-08189 in treatment-naive chronic hepatitis C patients with genotypes 2 and 3, assessing INX-08189 with pegylated interfero…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• INX-08189
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 2 | Status: TERMINATED